Research ExplorerPublicationsTargeting multiple myeloma with nanobody-based heavy chain a...

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors

Standard

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors. / Hambach, Julia; Mann, Anna Marei; Bannas, Peter; Koch-Nolte, Friedrich.

In: FRONT IMMUNOL, Vol. 13, 1005800, 2022.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Hambach, J, Mann, AM, Bannas, P & Koch-Nolte, F 2022, 'Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors', FRONT IMMUNOL, vol. 13, 1005800. https://doi.org/10.3389/fimmu.2022.1005800

APA

Hambach, J., Mann, A. M., Bannas, P., & Koch-Nolte, F. (2022). Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors. FRONT IMMUNOL, 13, [1005800]. https://doi.org/10.3389/fimmu.2022.1005800

Vancouver

Hambach J, Mann AM, Bannas P, Koch-Nolte F. Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors. FRONT IMMUNOL. 2022;13. 1005800. https://doi.org/10.3389/fimmu.2022.1005800

Bibtex

@article{14280c7b2f294a7ea7487d60d457f7b7,
title = "Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors",
abstract = "Nanobodies are well suited for constructing biologics due to their high solubility. We generated nanobodies directed against CD38, a tumor marker that is overexpressed by multiple myeloma and other hematological malignancies. We then used these CD38-specific nanobodies to construct heavy chain antibodies, bispecific killer cell engagers (BiKEs), chimeric antigen receptor (CAR)-NK cells, and nanobody-displaying AAV vectors. Here we review the utility of these nanobody-based constructs to specifically and effectively target CD38-expressing myeloma cells. The promising results of our preclinical studies warrant further clinical studies to evaluate the potential of these CD38-specific nanobody-based constructs for treatment of multiple myeloma.",
keywords = "Humans, Receptors, Chimeric Antigen/genetics, Multiple Myeloma/drug therapy, Antibodies, Bispecific/therapeutic use, ADP-ribosyl Cyclase 1, Single-Domain Antibodies, Immunoglobulin Heavy Chains/therapeutic use, Killer Cells, Natural",
author = "Julia Hambach and Mann, {Anna Marei} and Peter Bannas and Friedrich Koch-Nolte",
note = "Copyright {\textcopyright} 2022 Hambach, Mann, Bannas and Koch-Nolte.",
year = "2022",
doi = "10.3389/fimmu.2022.1005800",
language = "English",
volume = "13",
journal = "FRONT IMMUNOL",
issn = "1664-3224",
publisher = "Lausanne : Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors

AU - Hambach, Julia

AU - Mann, Anna Marei

AU - Bannas, Peter

AU - Koch-Nolte, Friedrich

N1 - Copyright © 2022 Hambach, Mann, Bannas and Koch-Nolte.

PY - 2022

Y1 - 2022

N2 - Nanobodies are well suited for constructing biologics due to their high solubility. We generated nanobodies directed against CD38, a tumor marker that is overexpressed by multiple myeloma and other hematological malignancies. We then used these CD38-specific nanobodies to construct heavy chain antibodies, bispecific killer cell engagers (BiKEs), chimeric antigen receptor (CAR)-NK cells, and nanobody-displaying AAV vectors. Here we review the utility of these nanobody-based constructs to specifically and effectively target CD38-expressing myeloma cells. The promising results of our preclinical studies warrant further clinical studies to evaluate the potential of these CD38-specific nanobody-based constructs for treatment of multiple myeloma.

AB - Nanobodies are well suited for constructing biologics due to their high solubility. We generated nanobodies directed against CD38, a tumor marker that is overexpressed by multiple myeloma and other hematological malignancies. We then used these CD38-specific nanobodies to construct heavy chain antibodies, bispecific killer cell engagers (BiKEs), chimeric antigen receptor (CAR)-NK cells, and nanobody-displaying AAV vectors. Here we review the utility of these nanobody-based constructs to specifically and effectively target CD38-expressing myeloma cells. The promising results of our preclinical studies warrant further clinical studies to evaluate the potential of these CD38-specific nanobody-based constructs for treatment of multiple myeloma.

KW - Humans

KW - Receptors, Chimeric Antigen/genetics

KW - Multiple Myeloma/drug therapy

KW - Antibodies, Bispecific/therapeutic use

KW - ADP-ribosyl Cyclase 1

KW - Single-Domain Antibodies

KW - Immunoglobulin Heavy Chains/therapeutic use

KW - Killer Cells, Natural

U2 - 10.3389/fimmu.2022.1005800

DO - 10.3389/fimmu.2022.1005800

M3 - SCORING: Review article

C2 - 36405759

VL - 13

JO - FRONT IMMUNOL

JF - FRONT IMMUNOL

SN - 1664-3224

M1 - 1005800

ER -